AVNT Stock Analysis: Avient | NYSE
Specialty Chemicals | NYSE, USA | Market Cap: 3.567m USD | 12M Return: 9.2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 39.4M
EPS Trend: 11.2%
Qual. Beats: 0
Rev. Trend: 48.0%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Avient Corporation (NYSE: AVNT) is a specialty formulator of material solutions headquartered in Avon Lake, Ohio, operating across the United States, Canada, Mexico, Europe, South America, and Asia. Founded in 1885 and formerly known as PolyOne Corporation until its June 2020 rebranding, the company runs through two reporting segments: Color, Additives and Inks, which supplies custom color and additive concentrates, dispersions, and specialty ink systems, and Specialty Engineered Materials, which provides tailored polymer formulations and solutions for thermoplastic processors.
The company serves a broad range of end markets, including medical and pharmaceutical devices, food packaging, personal care, transportation, building products, wire and cable, textiles, appliances, and industrial applications. As a B2B specialty chemicals producer, Avient sells primarily through direct sales personnel, distributors, and commissioned sales agents, focusing on customized, value-added formulations rather than commodity chemical output.
- Specialty Engineered Materials revenue grows on healthcare and aerospace demand
- Europe industrial slowdown pressures Color Additives and Inks volumes
- Raw material cost volatility squeezes specialty chemicals profit margins
| Net Income: 157.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 1.07 > 1.0 |
| NWC/Revenue: 18.92% < 20% (prev 22.61%; Δ -3.69% < -1%) |
| CFO/TA 0.05 > 3% & CFO 318.2m > Net Income 157.8m |
| Net Debt (1.57b) to EBITDA (483.5m): 3.26 < 3 |
| Current Ratio: 1.77 > 1.5 & < 3 |
| Outstanding Shares: last quarter (91.9m) vs 12m ago 0.44% < -2% |
| Gross Margin: 31.74% > 18% (prev 32.17%; Δ -0.43% > 0.5%) |
| Asset Turnover: 55.82% > 50% (prev 55.72%; Δ 0.10% > 0%) |
| Interest Coverage Ratio: 2.64 > 6 (EBIT TTM 295.0m / Interest Expense TTM 111.8m) |
| A: 0.10 (Total Current Assets 1.42b - Total Current Liabilities 803.1m) / Total Assets 5.94b |
| B: 0.32 (Retained Earnings 1.90b / Total Assets 5.94b) |
| C: 0.05 (EBIT TTM 295.0m / Avg Total Assets 5.88b) |
| D: 0.68 (Book Value of Equity 2.41b / Total Liabilities 3.53b) |
| Altman-Z'' = 2.78 = A |
| DSRI: 1.03 (Receivables 513.4m/489.6m, Revenue 3.28b/3.24b) |
| GMI: 1.01 (GM 32.17% / 31.74%) |
| AQI: 1.01 (AQ_t 0.60 / AQ_t-1 0.59) |
| SGI: 1.01 (Revenue 3.28b / 3.24b) |
| TATA: -0.03 (NI 157.8m - CFO 318.2m) / TA 5.94b) |
| Beneish M = -2.97 (Cap -4..+1) = A |
As of July 09, 2026, the stock is trading at USD 35.73 with a total of 1,005,846 shares traded. Over the past week, the price has changed by -3.33%, over one month by +4.37%, over three months by -2.84% and over the past year by +9.22%.
Current recommended Stop Loss: 34.10 (which is 4.6% or 1.3 ATR below the current price).
Avient has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy AVNT.
- StrongBuy: 4
- Buy: 0
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 47.1 | 31.9% |
P/E Trailing = 22.6105
P/E Forward = 12.0337
P/S = 1.087
P/B = 1.4223
P/EG = 1.224
Revenue TTM = 3.28b USD
EBIT TTM = 295.0m USD
EBITDA TTM = 483.5m USD
Long Term Debt = 1.92b USD (from longTermDebt, last quarter)
Short Term Debt = 500k USD (from shortTermDebt, last quarter)
Debt = 2.00b USD (from shortLongTermDebtTotal, last quarter) + Leases 77.3m
Net Debt = 1.57b USD (calculated: Debt 2.00b - CCE 427.6m)
Enterprise Value = 5.14b USD (3.57b + Debt 2.00b - CCE 427.6m)
Interest Coverage Ratio = 2.64 (Ebit TTM 295.0m / Interest Expense TTM 111.8m)
EV/FCF = 25.06x (Enterprise Value 5.14b / FCF TTM 205.1m)
FCF Yield = 3.99% (FCF TTM 205.1m / Enterprise Value 5.14b)
FCF Margin = 6.25% (FCF TTM 205.1m / Revenue TTM 3.28b)
Net Margin = 4.81% (Net Income TTM 157.8m / Revenue TTM 3.28b)
Gross Margin = 31.74% ((Revenue TTM 3.28b - Cost of Revenue TTM 2.24b) / Revenue TTM)
Gross Margin QoQ = 32.17% (prev 32.34%)
Tobins Q-Ratio = 0.86 (Enterprise Value 5.14b / Total Assets 5.94b)
Interest Expense / Debt = 5.58% (Interest Expense 111.8m / Debt 2.00b)
Taxrate = 24.36% (51.3m / 210.6m)
NOPAT = 223.1m (EBIT 295.0m * (1 - 24.36%))
Current Ratio = 1.77 (Total Current Assets 1.42b / Total Current Liabilities 803.1m)
Debt / Equity = 0.83 (Debt 2.00b / totalStockholderEquity, last quarter 2.41b)
Debt / EBITDA = 3.26 (Net Debt 1.57b / EBITDA 483.5m)
Debt / FCF = 7.68 (Net Debt 1.57b / FCF TTM 205.1m)
Total Stockholder Equity = 2.38b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.68% (Net Income 157.8m / Total Assets 5.94b)
RoE = 6.64% (Net Income TTM 157.8m / Total Stockholder Equity 2.38b)
RoCE = 6.86% (EBIT 295.0m / Capital Employed (Equity 2.38b + L.T.Debt 1.92b))
RoIC = 4.48% (NOPAT 223.1m / Invested Capital 4.98b)
WACC = 7.85% (E(3.57b)/V(5.57b) * Re(9.88%) + D(2.00b)/V(5.57b) * Rd(5.58%) * (1-Tc(0.24)))
Discount Rate = 9.88% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -26.26 | Cagr: 0.0%
[DCF] Terminal Value 77.97% ; FCFF base≈178.5m ; Y1≈204.6m ; Y5≈301.1m
[DCF] Fair Price = 32.24 (EV 4.53b - Net Debt 1.57b = Equity 2.96b / Shares 91.7m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 11.18 | EPS CAGR: 0.94% | SUE: 0.18 | # QB: 0
Revenue Correlation: 47.96 | Revenue CAGR: 0.89% | SUE: 0.10 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.89 | Chg30d=+0.00% | Revisions=+12% | Analysts=8
EPS next Quarter (2026-09-30): EPS=0.74 | Chg30d=-0.16% | Revisions=+0% | Analysts=8
EPS current Year (2026-12-31): EPS=3.07 | Chg30d=+0.00% | Revisions=+29% | GrowthEPS=+9.0% | GrowthRev=+3.8%
EPS next Year (2027-12-31): EPS=3.38 | Chg30d=+0.04% | Revisions=+0% | GrowthEPS=+10.0% | GrowthRev=+3.6%
[Analyst] Revisions Ratio: +17% (up=9, down=6)